« Previous
Next »
Titles
- REMS: FDA's application of statutory factors in determining when a REMS is necessary1
- Radiology contrast concerns: reports of extravasation and allergic reactions1
- Raising the bar: how California can use purchasing power and oversight to improve quality in Medi-Cal managed care1
- Re-approval of Kentucky Medicaid demonstration waiver1
- Ready or not: protecting the public's health from diseases, disasters and bioterrorism : 20191
- Ready or not?: protecting the public's health from diseases, disasters and bioterrorism : 20171
- Rebates for brand-name drugs in Part D substantially reduced the growth in spending from 2011 to 20151
- Recent Medicaid/CHIP enrollment declines and barriers to maintaining coverage1
- Recommendation followup: vulnerabilities continue to exist in the HHS small business innovation research program1
- Recommendations for reducing the risk of transfusion-transmitted babesiosis1
- Recommendations to improve access to mental health services for children with special health care needs in California1
- Recommended content and format of non-clinical bench performance testing information in premarket submissions: guidance for industry and Food and Drug Administration staff1
- Recommended statement for over-the-counter aspirin-containing drug products labeled with cardiovascular related imagery1
- Recurrent herpes labialis: developing drugs for treatment and prevention1
- Reducing educational debt among underrepresented physicians and dentists1
- Reducing potential overuse of dementia drugs could lead to considerable savings1
- Reducing the risk: final impact report1
- Reducing the risk: impact findings from the teen pregnancy prevention replication study : research brief1
- Reducing wasteful spending in employers' pharmacy benefit plans1
- Refuse to accept policy for 510(k)s: guidance for industry and Food and Drug Administration staff1